Publications by authors named "Michael Weiswasser"
Background: Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos.
Objective: Evaluate iberdomide efficacy and safety in cutaneous lupus erythematosus (CLE) in a phase 2 study.
Methods: Patients were randomized (2:2:1:2) to iberdomide 0.
Objectives: Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of transcription factors Ikaros () and Aiolos (). Pharmacodynamics and pharmacokinetics of oral iberdomide were evaluated in a phase 2b study of patients with active systemic lupus erythematosus (SLE).
Methods: Adults with autoantibody-positive SLE were randomised to placebo (n=83) or once daily iberdomide 0.
Article Synopsis
- Iberdomide is being tested as a treatment for systemic lupus erythematosus (SLE) by promoting the degradation of key transcription factors related to immune response.
- In a phase 2 trial, 288 patients were randomly assigned to receive iberdomide in different doses or a placebo for 24 weeks, evaluating the effectiveness through a specific index called SLE Responder Index (SRI-4).
- Results showed that 54% of patients taking the highest dose of iberdomide achieved a significant clinical response compared to 35% in the placebo group, though side effects mainly included infections and low white blood cell counts.
Objective: To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand that targets the hematopoietic transcription factors Ikaros and Aiolos for proteasomal degradation.
Methods: A 12-week, multicentre, double-blind, placebo-controlled, dose-escalation study in active SLE was followed by a 2-year, open-label active treatment extension phase (ATEP) (NCT02185040).